Achaogen Receives Investment from the Bill & Melinda Gates Foundation to Develop Antibodies Against Gram-Negative Bacteria

SOUTH SAN FRANCISCO, Calif., May 05, 2017 (GLOBE NEWSWIRE) — Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company developing novel antibacterials addressing multidrug-resistant (MDR) gram-negative infections, today announced that it has signed an agreement with the Bill & Melinda Gates Foundation (the Gates Foundation) to partner in efforts to prevent neonatal sepsis in developing countries through the generation of monoclonal antibodies against gram-negative bacteria. Neonatal sepsis, a bacterial bloodstream infection (BSI) in newborn babies, causes approximately 345,000 deaths per year worldwide.